ProQR Therapeutics N.V. (PRQR) creates transformative RNA therapeutics for treating Leber congenital amaurosis 10, retinitis pigmentosa, and Usher syndrome. The company’s pipeline is growing based on its novel proprietary RNA repair platform technologies.
The price of PRQR stock during the regular trading on February 10, 2022, was $5.64 with a 3.59% decline. At last check in the premarket on February 11, 2022, the stock further dipped by -70.21%.
PRQR: Events and Happenings
On February 11, 2022, PRQR updated about its Phase 2/3 Illuminate clinical trial of sepofarsen for treating LCA10. The company did not meet the primary endpoint of BCVA in the 12th Month.
PRQR: CEO Comments
Speaking at the occasion, PRQR’s CEO Daniel A. de Boer stated that the outcomes are disappointing and surprising. He further added that the company will continue to advance its vigorous therapeutics pipeline for genetic eye disease.
On February 07, 2022, PRQR updated about the company’s Executive management’s presentation at the SVB Leerink 11th Annual Virtual Global Healthcare Conference being held on February 17, 2022. On December 30, 2021, PRQR reported about the amendment in its convertible debt financing contract with Kreos Capital and Pontifax Medison Debt Financing.
On December 16, 2021, PRQR announced the dosage of preliminary patients in Phase 2/3 Sirius and Celeste studies. On November 11, 2021, PRQR updated about its virtual Analyst Event webcast held on November 18, 2021. On November 08, 2021, PRQR reported about its management’s participation at the following investor conferences
- Stifel 2021 Virtual Healthcare Conference on November 15, and
- Evercore ISI 4th Annual HealthCONx Conference on December 2, 2021.
PRQR: Key Financials
On November 4, 2021, PRQR released its financial results for the third quarter ended September 30, 2021. Some of the main points are mentioned here.
EPS
Basic and diluted net loss per share in the Q3 2021 was €15.1 million or €0.22 against €13.2 million or €0.26 in the same quarter of 2020. The net loss decreased over the period of the year. The company’s EPS was in-line with the analysts’ estimates.
Revenue
Revenue for three months ended in 2021 was €0.87 million compared to no revenue in the same period of 2020. The company beat the analysts’ estimates by $1.06 million.
Conclusion
PRQR stock is 12% up the past year. The recent premarket dip in the stock is the result of disappointing clinical results for Illuminate trials of sepofarsen. The company is much disappointed as it did not meet the primary endpoint. As the earnings release date is approaching, the analysts are expecting the company’s revenue and EPS to be $4.17 million and -$0.12 per share respectively.
